Soppa U - Search Results

1

The impact of C-reactive protein levels on the effectiveness of upadacitinib in patients with rheumatoid arthritis: a 12-month prospective, non-interventional German study.

Witte T, Kiltz U, Haas F, Riechers E, Prothmann U, Adolf D, Holland C, Rössler A, Soppa U, Fritz B, Götz K, Krüger K; UPwArds Study Group. Witte T, et al. Among authors: soppa u. Clin Exp Rheumatol. 2024 Mar;42(3):726-735. doi: 10.55563/clinexprheumatol/11255h. Epub 2023 Nov 15. Clin Exp Rheumatol. 2024. PMID: 37976112 Free article.

2

Oral administration of methysticin improves cognitive deficits in a mouse model of Alzheimer's disease.

Fragoulis A, Siegl S, Fendt M, Jansen S, Soppa U, Brandenburg LO, Pufe T, Weis J, Wruck CJ. Fragoulis A, et al. Among authors: soppa u. Redox Biol. 2017 Aug;12:843-853. doi: 10.1016/j.redox.2017.04.024. Epub 2017 Apr 19. Redox Biol. 2017. PMID: 28448946 Free PMC article.

3

DYRK protein kinases.

Soppa U, Becker W. Soppa U, et al. Curr Biol. 2015 Jun 15;25(12):R488-9. doi: 10.1016/j.cub.2015.02.067. Curr Biol. 2015. PMID: 26079075 Free article.

4

Effect of tyrosine autophosphorylation on catalytic activity and subcellular localisation of homeodomain-interacting protein kinases (HIPK).

van der Laden J, Soppa U, Becker W. van der Laden J, et al. Among authors: soppa u. Cell Commun Signal. 2015 Jan 29;13:3. doi: 10.1186/s12964-014-0082-6. Cell Commun Signal. 2015. PMID: 25630557 Free PMC article.

5

The Down syndrome-related protein kinase DYRK1A phosphorylates p27(Kip1) and Cyclin D1 and induces cell cycle exit and neuronal differentiation.

Soppa U, Schumacher J, Florencio Ortiz V, Pasqualon T, Tejedor FJ, Becker W. Soppa U, et al. Cell Cycle. 2014;13(13):2084-100. doi: 10.4161/cc.29104. Epub 2014 May 7. Cell Cycle. 2014. PMID: 24806449 Free PMC article.

6

DYRK1A: a potential drug target for multiple Down syndrome neuropathologies.

Becker W, Soppa U, Tejedor FJ. Becker W, et al. Among authors: soppa u. CNS Neurol Disord Drug Targets. 2014 Feb;13(1):26-33. doi: 10.2174/18715273113126660186. CNS Neurol Disord Drug Targets. 2014. PMID: 24152332 Review.

7

NGF upregulates the plasminogen activation inhibitor-1 in neurons via the calcineurin/NFAT pathway and the Down syndrome-related proteins DYRK1A and RCAN1 attenuate this effect.

Stefos GC, Soppa U, Dierssen M, Becker W. Stefos GC, et al. Among authors: soppa u. PLoS One. 2013 Jun 25;8(6):e67470. doi: 10.1371/journal.pone.0067470. Print 2013. PLoS One. 2013. PMID: 23825664 Free PMC article.

8

Sulforaphane has opposing effects on TNF-alpha stimulated and unstimulated synoviocytes.

Fragoulis A, Laufs J, Müller S, Soppa U, Siegl S, Reiss LK, Tohidnezhad M, Rosen C, Tenbrock K, Varoga D, Lippross S, Pufe T, Wruck CJ. Fragoulis A, et al. Among authors: soppa u. Arthritis Res Ther. 2012 Oct 27;14(5):R220. doi: 10.1186/ar4059. Arthritis Res Ther. 2012. PMID: 23072510 Free PMC article.

9

Harmine specifically inhibits protein kinase DYRK1A and interferes with neurite formation.

Göckler N, Jofre G, Papadopoulos C, Soppa U, Tejedor FJ, Becker W. Göckler N, et al. Among authors: soppa u. FEBS J. 2009 Nov;276(21):6324-37. doi: 10.1111/j.1742-4658.2009.07346.x. Epub 2009 Oct 1. FEBS J. 2009. PMID: 19796173 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

9 results

Search Page